Senores Pharmaceuticals IPO Details: A Comprehensive Overview

Senores Pharmaceuticals is set to launch its highly anticipated Initial Public Offering (IPO) from December 20, 2024, to December 24, 2024. With a strong presence in the global pharmaceutical industry, this IPO offers investors an opportunity to become part of a growing company focused on regulated markets like the United States, Canada, and the United Kingdom. Here’s everything you need to know about the Senores Pharmaceuticals IPO.

Senores Pharmaceuticals IPO Overview

• IPO Open Date: December 20, 2024
• IPO Close Date: December 24, 2024
• Price Band: ₹372 to ₹391 per share
• Lot Size: 38 shares
• Total Issue Size: ₹582.11 Cr
• Fresh Issue: ₹500 Cr (1,27,87,723 shares)
• Offer for Sale: ₹82.11 Cr (21,00,000 shares)
• Face Value: ₹10 per share
• Issue Type: Book Built Issue IPO
• Listing At: BSE, NSE
• Expected Listing Date: December 30, 2024

Also See IPO GMP and Subscription

About Senores Pharmaceuticals

Founded in 2017, Senores Pharmaceuticals has quickly established itself as a reliable manufacturer of pharmaceutical products across various therapeutic areas and dosage forms. The company serves regulated markets, including the US, Canada, and the UK, and has a product portfolio featuring medications such as Acetaminophen Butalbital, Chlorzoxazone, Diclofenac Potassium, Ketorolac, and Mexiletine Hydrochloride.

Senores Pharmaceuticals also provides Contract Development and Manufacturing Organisation (CDMO) and Contract Manufacturing Organisation (CMO) services from its Atlanta facility, strengthening its presence in North America and Europe.

• Managing Director: Mr. Swapnil Jatinbhai Shah
• Parent Organisation: Senores Pharmaceuticals Ltd

Also Read: Carraro India IPO Details: All You Need to Know

Senores Pharmaceuticals Financials

The financial growth of Senores Pharmaceuticals showcases its potential as a promising investment opportunity.

Revenue in ₹ Cr:

• 2022: ₹14.17
• 2023: ₹35.34
• 2024: ₹215.00

Total Assets in ₹ Cr:

• 2022: ₹59.15
• 2023: ₹131.00
• 2024: ₹622.00

Profit in ₹ Cr:

• 2022: ₹0.99
• 2023: ₹8.43
• 2024: ₹32.71

Key Financial Metrics

The market capitalization of Senores Pharmaceuticals IPO is ₹1,350.70 Cr.

Key Performance Indicators (as of March 31, 2024):

• ROE (Return on Equity): 23.60%
• ROCE (Return on Capital Employed): 11.73%
• Debt-to-Equity Ratio: 1.07
• PAT Margin: 15.25%
• Price-to-Book Value: 5.84

Also Read: Unimech Aerospace IPO Details: A Comprehensive Investment Guide

Senores Pharmaceuticals IPO Lot Size and Investment

Investors can bid in lots of 38 shares. Below is a detailed investment breakdown for retail and HNI investors.

Retail Investors:

• Minimum Lot: 38 shares | ₹14,858
• Maximum Lot: 494 shares | ₹1,93,154

S-HNI Investors:

• Minimum Lot: 532 shares | ₹2,08,012
• Maximum Lot: 2,546 shares | ₹9,95,486

B-HNI Investors:

• Minimum Lot: 2,584 shares | ₹10,10,344

Senores Pharmaceuticals IPO Promoter Holding

• Pre-Issue Holding: 3,32,65,865 shares (100%)
• Post-Issue Holding: 4,60,53,588 shares (72.20%)

The promoters include Senores Pharmaceuticals Ltd, ensuring continued strong backing and vision for future growth.

Senores Pharmaceuticals IPO Timeline

• IPO Open Date: December 20, 2024
• IPO Close Date: December 24, 2024
• Basis of Allotment: December 26, 2024
• Initiation of Refunds: December 27, 2024
• Credit of Shares to Demat: December 27, 2024
• Listing Date: December 30, 2024

Why Invest in Senores Pharmaceuticals IPO?

Strengths:

• Rapid Growth: Significant revenue and profit increase from 2022 to 2024.
• Global Presence: Operations in regulated markets (US, Canada, UK).
• Diversified Offerings: Robust product portfolio and CDMO/CMO services.
• High ROE: Strong return on equity highlights financial health.

Risks:

• High Debt: Debt-to-equity ratio of 1.07 indicates moderate financial leverage.
• Sector-Specific Challenges: Dependency on regulated markets and compliance requirements.

Registrar Details

• Registrar: Link Intime India Private Ltd
• Phone: +91-22-4918 6270
• Email: senorespharma.ipo@linkintime.co.in
• Website: Link Intime IPO Page

Conclusion

The Senores Pharmaceuticals IPO presents a lucrative opportunity for investors looking to tap into the global pharmaceutical market. With a strong financial performance, diversified product portfolio, and robust market presence, the company is poised for growth. However, potential investors should carefully evaluate the risks and perform due diligence before applying.

Stay tuned for updates on allotment status, GMP (Grey Market Premium), and listing performance for Senores Pharmaceuticals IPO!

FAQs